Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333057 · ClinicalTrials.gov registry record · Phase 2
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT03333057: Completed Phase 2 study, sponsored by Novaliq.
NCT03333057 is a Phase 2 study that has completed, run by Novaliq. The registered enrollment target is 336 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03333057, a Phase 2 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Primary Outcome
The primary efficacy variable was comparison of absolute and change from baseline between treatments for total Corneal Fluorescein Staining (tCFS) according to the National Eye Institute grading (NEI Scale) at week 8 The NEI Scale is a standardized grading system. 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.
Interventions
- DRUG Placebo
- DRUG NOV03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 2 |
What the finished NCT03333057 record still lists
NCT03333057 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03333057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03333057 about?
NCT03333057 is a clinical study titled "Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
What is the current status of trial NCT03333057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2018-01-03. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03333057?
The interventions under investigation include: Placebo (DRUG), NOV03 (DRUG).
Who is sponsoring clinical trial NCT03333057?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03333057's enrollment target sits among peer trials
336 141st of 2000 higher than 1,859 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI